Oncorus Announces Appointment of Richard Wanstall as Chief Financial Officer

$ONCR
Medicinal Chemicals and Botanical Products
Health Care
Get the next $ONCR alert in real time by email

CAMBRIDGE, Mass., May 10, 2022 (GLOBE NEWSWIRE) -- Oncorus, Inc. (NASDAQ:ONCR), a viral immunotherapy company focused on driving innovation to transform outcomes for cancer patients, today announced the appointment of Richard Wanstall as Chief Financial Officer.

"We are pleased to welcome Rick as our Chief Financial Officer and we look forward to drawing from his notable experience leading biotech companies through significant organizational growth," said Theodore (Ted) Ashburn, M.D., Ph.D., President and Chief Executive Officer of Oncorus. "Rick is a trusted colleague that I, as well as other members of the senior leadership team, have had the pleasure of working alongside in our previous roles. I am confident that his deep understanding of the biotech industry, specifically his expertise in life sciences corporate strategy and financing, will be a vital addition to Oncorus as our business matures. On behalf of the entire leadership team, we are excited to work with Rick to achieve our shared goal of meaningfully improving the current standard of care for cancer patients."

"I'm excited to join the Oncorus team and to work in tandem with such a credentialed group of industry leaders to advance the company's innovative HSV and selectively self-amplifying vRNA/LNP platform technologies," said Mr. Wanstall. "Oncorus is at a critical time in its development with key data readouts from ONCR-177 expected later this year, ongoing IND-enabling studies for ONCR-021, a state-of-the art GMP manufacturing facility nearing completion and a cash runway into early 2024. Taken together, Oncorus is uniquely positioned to execute on their viral immunotherapeutic approach to cancer treatment, and I look forward to contributing my skillset to drive value for shareholders and bring this innovative technology to patients in need."

Mr. Wanstall brings over 25 years of financial and operations experience to Oncorus. Most recently, he served as Chief Financial Officer and Treasurer for Aileron Therapeutics, where he was responsible for overseeing the company's strategy, finance, investor relations, and operations activities. Prior to Aileron, Mr. Wanstall served as Vice President of Finance at Moderna Therapeutics and as Senior Vice President of Finance at Stream Global Services. Previously, Mr. Wanstall was Vice President of Finance at Art Technology Group, a Vice President at Taxware, and Director of Finance at CNET. He began his career in various financial roles at John Hancock, Fidelity Investments, and PricewaterhouseCoopers. Mr. Wanstall holds an M.B.A. from Babson College and a B.A. in Accounting from Salem State University.

About Oncorus

At Oncorus, we are focused on driving innovation to deliver next-generation viral immunotherapies to transform outcomes for cancer patients. We are advancing a portfolio of intratumorally (iTu) and intravenously (IV) administered viral immunotherapies for multiple indications with significant unmet need based on our Herpes Simplex Virus (HSV) and selectively self-amplifying viral RNA (vRNA) Immunotherapy Platforms.

Designed to deliver next-generation viral immunotherapy impact, our HSV Platform improves upon key characteristics of this therapeutic class to enhance systemic activity. Our lead HSV program, ONCR-177, is designed to be directly administered into a tumor, resulting in high local concentrations of the therapeutic agent and its five encoded transgenes, as well as low systemic exposure to the therapy, which could limit systemic toxicities. Our pioneering selectively self-amplifying vRNA Immunotherapy Platform, highlighted by our product candidates ONCR-021 and ONCR-788, involves a highly innovative, novel combination of RNA and oncolytic virus-based modalities designed to realize the potential of RNA medicines for cancer.

Please visit www.oncorus.com to learn more.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, implied and express statements regarding Oncorus' near-term milestones, including data readouts from the ongoing clinical trial of ONCR-177, the planned IND submission for ONCR-021, the completion of Oncorus' facility in Andover, Massachusetts and the Oncorus' cash runway. The words "may," "might," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "expect," "estimate," "seek," "predict," "future," "project," "potential," "continue," "target" and similar words or expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, risks associated with: Oncorus' ability to successfully demonstrate the safety, tolerability and efficacy of ONCR-177, ONCR-021, ONCR-788 and ONCR-GBM and obtain regulatory approval thereof; the impact of COVID-19 on Oncorus' operations and the timing and anticipated results of its ongoing and planned clinical trials; Oncorus' ability to obtain the requisite components for its product candidates manufactured in accordance with regulatory requirements; Oncorus' planned facility consolidation and the expansion of Oncorus' in-house manufacturing capabilities; the adequacy of Oncorus' existing capital resources and availability of financing on commercially reasonable terms; the accuracy of the Oncorus' estimates regarding expenses, future revenue, capital requirements and needs for additional financing; and Oncorus' ability to obtain, maintain and protect its intellectual property. These and other risks and uncertainties are described in greater detail in the section entitled "Risk Factors" in Oncorus' Annual Report on Form 10-K for the year ended December 31, 2021, filed with the Securities and Exchange Commission (SEC) on March 9, 2022, and Oncorus' Quarterly Report on Form 10-Q for the quarter ended March 31, 2022, filed with the SEC on May 4, 2022, as well as discussions of potential risks, uncertainties, and other important factors in the other filings that Oncorus makes with the SEC from time to time. These documents are available under the "SEC filings" page of the Investors section of Oncorus' website at http://investors.oncorus.com. Any forward-looking statements represent Oncorus' views only as of the date of this press release and should not be relied upon as representing its views as of any subsequent date. Oncorus explicitly disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.

        

Investor Contact:

Stern Investor Relations

Julie Seidel

Julie.seidel@sternir.com



Primary Logo

Get the next $ONCR alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$ONCR

DatePrice TargetRatingAnalyst
More analyst ratings

$ONCR
Press Releases

Fastest customizable press release news feed in the world

See more
  • Oncorus Announces Workforce Reduction Plan

    ANDOVER, Mass., June 01, 2023 (GLOBE NEWSWIRE) -- Oncorus, Inc. (NASDAQ:ONCR), an RNA medicines company focused on developing intravenously administered, self-amplifying RNA to transform outcomes for cancer patients, today announced that, in response to challenges associated with raising additional capital and pursuing strategic alternatives to secure additional funding, including current market conditions, the Company's board of directors has approved a workforce reduction of approximately 55 employees, representing substantially all of Oncorus' workforce, which is expected to be completed by August 2023. Theodore (Ted) Ashburn, M.D., Ph.D. (Chief Executive Officer), Stephen W. Harbin (C

    $ONCR
    Medicinal Chemicals and Botanical Products
    Health Care
  • Oncorus Reports First Quarter 2023 Financial Results and Provides Business Updates

    IND submission for ONCR-021 still planned for mid-2023, subject to receipt of additional funding Ended the quarter with $45.0 million in cash, cash equivalents and investments ANDOVER, Mass., May 22, 2023 (GLOBE NEWSWIRE) -- Oncorus, Inc. (NASDAQ:ONCR), an RNA medicines company focused on developing intravenously administered, self-amplifying RNA to transform outcomes for cancer patients, today reported first quarter financial results and provided an update on its business. "Oncorus is pioneering a first-of-its-kind, self-amplifying RNA platform with an exciting lead program, ONCR-021, with plans to submit an IND with the FDA in mid-2023," said Theodore (Ted) Ashburn, M.D., Ph.D., Pres

    $ONCR
    Medicinal Chemicals and Botanical Products
    Health Care
  • Oncorus Announces Research Collaboration with Daewoong Pharmaceutical for the Development of Lipid Nanoparticle Formulations for mRNA Drug Candidates

    Research collaboration leverages Oncorus' proprietary ionizable amines, PEG lipids, LNP formulations, process development and manufacturing together with Daewoong's mRNA expertiseOpportunity for future license, manufacturing and supply agreement for formulated drug candidates ANDOVER, Mass., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Oncorus, Inc. (NASDAQ:ONCR), an RNA medicines company focused on developing intravenously administered, self-amplifying RNA to transform outcomes for cancer patients, and Daewoong Pharmaceutical Co., Ltd. (KRX: 069620), a leading South Korean pharmaceutical company, today announced a research collaboration for the discovery and development of novel lipid nanoparticle

    $ONCR
    Medicinal Chemicals and Botanical Products
    Health Care

$ONCR
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$ONCR
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$ONCR
SEC Filings

See more

$ONCR
Leadership Updates

Live Leadership Updates

See more
  • Oncorus Reports First Quarter 2023 Financial Results and Provides Business Updates

    IND submission for ONCR-021 still planned for mid-2023, subject to receipt of additional funding Ended the quarter with $45.0 million in cash, cash equivalents and investments ANDOVER, Mass., May 22, 2023 (GLOBE NEWSWIRE) -- Oncorus, Inc. (NASDAQ:ONCR), an RNA medicines company focused on developing intravenously administered, self-amplifying RNA to transform outcomes for cancer patients, today reported first quarter financial results and provided an update on its business. "Oncorus is pioneering a first-of-its-kind, self-amplifying RNA platform with an exciting lead program, ONCR-021, with plans to submit an IND with the FDA in mid-2023," said Theodore (Ted) Ashburn, M.D., Ph.D., Pres

    $ONCR
    Medicinal Chemicals and Botanical Products
    Health Care
  • Oncorus Appoints Douglas Fambrough to Board of Directors

    -Former CEO of Dicerna brings deep expertise in RNA research, drug development, business development and financing- CAMBRIDGE, Mass., June 23, 2022 (GLOBE NEWSWIRE) -- Oncorus, Inc. (NASDAQ:ONCR), a viral immunotherapies company focused on driving innovation to transform outcomes for cancer patients, today announced the appointment of Douglas M. Fambrough, III, Ph.D. to its board of directors. "We are thrilled to welcome Doug to our board and leverage his significant expertise and executive leadership skills as we work to advance our next-generation HSV and selectively self-amplifying vRNA/LNP platforms," said Theodore (Ted) Ashburn, M.D., Ph.D., President and Chief Executive Officer

    $ONCR
    Medicinal Chemicals and Botanical Products
    Health Care
  • Oncorus Announces Appointment of Richard Wanstall as Chief Financial Officer

    CAMBRIDGE, Mass., May 10, 2022 (GLOBE NEWSWIRE) -- Oncorus, Inc. (NASDAQ:ONCR), a viral immunotherapy company focused on driving innovation to transform outcomes for cancer patients, today announced the appointment of Richard Wanstall as Chief Financial Officer. "We are pleased to welcome Rick as our Chief Financial Officer and we look forward to drawing from his notable experience leading biotech companies through significant organizational growth," said Theodore (Ted) Ashburn, M.D., Ph.D., President and Chief Executive Officer of Oncorus. "Rick is a trusted colleague that I, as well as other members of the senior leadership team, have had the pleasure of working alongside in our previ

    $ONCR
    Medicinal Chemicals and Botanical Products
    Health Care

$ONCR
Financials

Live finance-specific insights

See more
  • Oncorus Announces Portfolio Reprioritization to Focus on IV-Administered, Self-Amplifying RNA Medicines for Patients with Cancer

    Company now focused on the development of ONCR-021, Oncorus' lead self-amplifying RNA product candidate for non-small cell lung and other cancers; program remains on track for IND submission in mid-2023Phase 1 clinical trial of ONCR-177 in patients with advanced disease is being discontinuedPrioritization of ONCR-021 and reduction in workforce reduces company's cash burn rate; Oncorus reiterates guidance of cash runway into early 2024 ANDOVER, Mass., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Oncorus, Inc. (NASDAQ:ONCR), an RNA medicines company focused on developing IV administered, self-amplifying RNA to transform outcomes for cancer patients, today announced that it is reprioritizing its pipeli

    $ONCR
    Medicinal Chemicals and Botanical Products
    Health Care
  • Oncorus Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Updates

    Data presented from ongoing Phase 1 clinical trial of ONCR-177 in multiple solid tumor indications at RP2D at SITC 2021 and preclinical studies of ONCR-GBM targeting brain cancer at IOVC 2021Signed exclusive licensing agreement with Gaeta Therapeutics for use of locally delivered IL-12 via oncolytic viral expression in combination with immune checkpoint inhibitorsAdditional clinical data from ONCR-177 surface lesion monotherapy expansion and combination expansion cohorts expected in second half of 2022Continued to advance preclinical programs, including ONCR-021 towards IND filing in mid-2023Strengthened executive leadership team with promotion of John Goldberg, M.D., to Chief Medical Office

    $ONCR
    Medicinal Chemicals and Botanical Products
    Health Care
  • Oncorus Reports Initial Safety, Tolerability, Immune Activation and Positive Clinical Response Data from its Ongoing Phase 1 Clinical Study of ONCR-177, its Lead Viral Immunotherapy Candidate, at SITC 2021

    ONCR-177 was well tolerated with no dose-limiting toxicities in the surface lesion dose escalation part of the first-in-human study in heavily pretreated patients with advanced, injectable solid tumorsRecommended Phase 2 dose (RP2D) selected and expansion monotherapy cohort dosing is underwayThree of eight evaluable patients at RP2D across multiple indications (cutaneous melanoma, head and neck cancer, and mucosal melanoma) experienced clinical benefit after two doses of single-agent ONCR-177Proof of principle established for propriety Herpes Simplex Virus (HSV) platform that leverages microRNA attenuation to enable interferon resistance via retention of γ34.5 and five complementary immunomo

    $ONCR
    Medicinal Chemicals and Botanical Products
    Health Care

$ONCR
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more